Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Anti-HIV Agents | 6 | 2019 | 2209 | 1.51 | Why? |
| Polymorphism, Single Nucleotide | 4 | 2019 | 3607 | 1.10 | Why? |
| Chemical and Drug Induced Liver Injury | 2 | 2019 | 451 | 1.00 | Why? |
| Drug Resistance, Viral | 4 | 2019 | 1083 | 0.98 | Why? |
| Nevirapine | 2 | 2019 | 57 | 0.94 | Why? |
| Cytochrome P-450 CYP2B6 | 1 | 2019 | 12 | 0.80 | Why? |
| Spotted Fever Group Rickettsiosis | 1 | 2018 | 11 | 0.78 | Why? |
| Typhus, Epidemic Louse-Borne | 1 | 2018 | 17 | 0.77 | Why? |
| Cytochrome P-450 CYP2D6 | 1 | 2018 | 28 | 0.77 | Why? |
| India | 35 | 2020 | 11875 | 0.76 | Why? |
| Endosomal Sorting Complexes Required for Transport | 1 | 2018 | 67 | 0.74 | Why? |
| Mutagenesis, Insertional | 1 | 2018 | 92 | 0.73 | Why? |
| HIV-1 | 7 | 2018 | 3365 | 0.70 | Why? |
| Cytochrome P-450 CYP2C9 | 1 | 2017 | 25 | 0.69 | Why? |
| HIV Infections | 10 | 2019 | 11620 | 0.69 | Why? |
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2018 | 95 | 0.69 | Why? |
| Calcium-Binding Proteins | 1 | 2018 | 121 | 0.69 | Why? |
| Eligibility Determination | 1 | 2020 | 255 | 0.69 | Why? |
| Cytochrome P-450 CYP1A1 | 1 | 2017 | 39 | 0.69 | Why? |
| Matrix Metalloproteinase 7 | 1 | 2016 | 21 | 0.66 | Why? |
| Monitoring, Immunologic | 1 | 2017 | 153 | 0.64 | Why? |
| Virus Release | 1 | 2018 | 253 | 0.63 | Why? |
| AIDS Dementia Complex | 1 | 2016 | 48 | 0.62 | Why? |
| Cell Cycle Proteins | 1 | 2018 | 297 | 0.62 | Why? |
| Polymorphism, Restriction Fragment Length | 3 | 2018 | 116 | 0.50 | Why? |
| Promoter Regions, Genetic | 1 | 2016 | 823 | 0.48 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.45 | Why? |
| Time | 10 | 2020 | 631 | 0.43 | Why? |
| Disease Susceptibility | 1 | 2020 | 4002 | 0.32 | Why? |
| Reverse Transcriptase Inhibitors | 3 | 2017 | 309 | 0.32 | Why? |
| Alcohol Drinking | 1 | 2018 | 1663 | 0.32 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.29 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.28 | Why? |
| Genotyping Techniques | 2 | 2017 | 360 | 0.27 | Why? |
| Liver | 1 | 2018 | 4007 | 0.26 | Why? |
| CD4 Lymphocyte Count | 3 | 2019 | 1517 | 0.26 | Why? |
| Viral Load | 4 | 2020 | 15850 | 0.25 | Why? |
| Gene Frequency | 2 | 2018 | 1210 | 0.24 | Why? |
| Disease Models, Animal | 1 | 2020 | 10998 | 0.23 | Why? |
| Genotype | 3 | 2018 | 4697 | 0.23 | Why? |
| Antiretroviral Therapy, Highly Active | 2 | 2017 | 952 | 0.23 | Why? |
| Genetic Predisposition to Disease | 1 | 2016 | 4027 | 0.22 | Why? |
| T-Lymphocytes | 1 | 2019 | 6670 | 0.22 | Why? |
| HIV Reverse Transcriptase | 2 | 2019 | 104 | 0.22 | Why? |
| Distemper Virus, Canine | 1 | 2019 | 40 | 0.20 | Why? |
| Lions | 1 | 2019 | 41 | 0.20 | Why? |
| Topography, Medical | 1 | 2019 | 45 | 0.20 | Why? |
| pol Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 39 | 0.20 | Why? |
| Alkynes | 1 | 2019 | 98 | 0.20 | Why? |
| Case-Control Studies | 5 | 2020 | 17671 | 0.19 | Why? |
| Biotransformation | 1 | 2018 | 74 | 0.19 | Why? |
| Turbinates | 1 | 2020 | 205 | 0.19 | Why? |
| Benzoxazines | 1 | 2019 | 103 | 0.19 | Why? |
| HIV-2 | 1 | 2019 | 92 | 0.18 | Why? |
| Strategic Planning | 1 | 2020 | 122 | 0.18 | Why? |
| Thymidine | 1 | 2017 | 21 | 0.18 | Why? |
| Rickettsia | 1 | 2018 | 101 | 0.18 | Why? |
| Nipah Virus | 1 | 2019 | 121 | 0.18 | Why? |
| Scrub Typhus | 1 | 2018 | 68 | 0.18 | Why? |
| Henipavirus Infections | 1 | 2019 | 122 | 0.17 | Why? |
| HIV Long-Term Survivors | 1 | 2017 | 56 | 0.17 | Why? |
| Sex Work | 1 | 2018 | 96 | 0.17 | Why? |
| Animal Diseases | 1 | 2019 | 182 | 0.17 | Why? |
| Pneumonia, Viral | 15 | 2020 | 243684 | 0.17 | Why? |
| Coronavirus Infections | 15 | 2020 | 253789 | 0.16 | Why? |
| Cyclopropanes | 1 | 2019 | 332 | 0.16 | Why? |
| Spleen | 1 | 2020 | 877 | 0.15 | Why? |
| Sentinel Surveillance | 2 | 2020 | 1093 | 0.14 | Why? |
| DNA Mutational Analysis | 1 | 2017 | 581 | 0.14 | Why? |
| Trachea | 1 | 2020 | 894 | 0.14 | Why? |
| Antibodies, Bacterial | 1 | 2018 | 510 | 0.14 | Why? |
| Sequence Deletion | 1 | 2018 | 674 | 0.13 | Why? |
| Disease Outbreaks | 2 | 2019 | 27595 | 0.13 | Why? |
| Ethanol | 1 | 2019 | 533 | 0.13 | Why? |
| Mutation | 3 | 2019 | 12376 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Humans | 42 | 2020 | 930598 | 0.12 | Why? |
| Virus Latency | 1 | 2014 | 251 | 0.12 | Why? |
| Alleles | 1 | 2018 | 1557 | 0.12 | Why? |
| Betacoronavirus | 15 | 2020 | 204454 | 0.12 | Why? |
| Cricetinae | 1 | 2020 | 3344 | 0.12 | Why? |
| Adult | 16 | 2020 | 244371 | 0.11 | Why? |
| Polymerase Chain Reaction | 2 | 2017 | 6740 | 0.11 | Why? |
| Seroepidemiologic Studies | 4 | 2020 | 10017 | 0.11 | Why? |
| Immunoglobulin G | 3 | 2020 | 21571 | 0.11 | Why? |
| Female | 19 | 2021 | 380317 | 0.10 | Why? |
| Male | 18 | 2021 | 367725 | 0.10 | Why? |
| Drug Combinations | 1 | 2020 | 3852 | 0.10 | Why? |
| Mice, Inbred BALB C | 1 | 2020 | 5814 | 0.10 | Why? |
| Mice, Inbred C57BL | 1 | 2020 | 5542 | 0.10 | Why? |
| T-Lymphocyte Subsets | 1 | 2017 | 1387 | 0.09 | Why? |
| Health Personnel | 12 | 2020 | 29646 | 0.09 | Why? |
| Gene Expression | 1 | 2018 | 3332 | 0.09 | Why? |
| Immune System | 1 | 2017 | 1479 | 0.09 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.08 | Why? |
| Real-Time Polymerase Chain Reaction | 4 | 2020 | 11367 | 0.08 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Middle Aged | 11 | 2020 | 270681 | 0.08 | Why? |
| Pandemics | 26 | 2020 | 389249 | 0.08 | Why? |
| Guidelines as Topic | 1 | 2020 | 2844 | 0.08 | Why? |
| Kidney | 1 | 2020 | 3648 | 0.07 | Why? |
| Young Adult | 8 | 2020 | 93724 | 0.07 | Why? |
| Adolescent | 8 | 2020 | 86841 | 0.07 | Why? |
| Immunity, Humoral | 1 | 2020 | 4849 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| Immunologic Memory | 1 | 2017 | 3362 | 0.07 | Why? |
| HEK293 Cells | 1 | 2018 | 8394 | 0.07 | Why? |
| Antibodies, Viral | 4 | 2021 | 51949 | 0.07 | Why? |
| Reproducibility of Results | 2 | 2020 | 11304 | 0.07 | Why? |
| Chiroptera | 1 | 2019 | 3530 | 0.07 | Why? |
| Circumcision, Male | 1 | 2004 | 57 | 0.07 | Why? |
| Cross-Sectional Studies | 4 | 2020 | 53120 | 0.07 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.06 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.06 | Why? |
| Mass Screening | 2 | 2020 | 8005 | 0.06 | Why? |
| Phylogeny | 2 | 2020 | 13341 | 0.06 | Why? |
| Pharynx | 2 | 2020 | 1544 | 0.06 | Why? |
| MicroRNAs | 1 | 2014 | 1787 | 0.06 | Why? |
| Fever | 1 | 2018 | 7795 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Drug Repositioning | 1 | 2020 | 5683 | 0.05 | Why? |
| Models, Theoretical | 1 | 2020 | 6659 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.05 | Why? |
| Genome, Viral | 2 | 2020 | 13157 | 0.05 | Why? |
| Clinical Laboratory Techniques | 4 | 2020 | 23402 | 0.05 | Why? |
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 7868 | 0.05 | Why? |
| Mice | 1 | 2020 | 21357 | 0.05 | Why? |
| Communicable Disease Control | 2 | 2020 | 29620 | 0.05 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2020 | 13720 | 0.05 | Why? |
| HIV Protease | 1 | 2019 | 86 | 0.05 | Why? |
| Animals | 4 | 2021 | 78931 | 0.05 | Why? |
| Public Sector | 1 | 2020 | 204 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Public Health | 2 | 2020 | 16359 | 0.04 | Why? |
| Automation, Laboratory | 1 | 2020 | 536 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Quality Control | 1 | 2020 | 628 | 0.04 | Why? |
| Sexually Transmitted Diseases | 1 | 2004 | 694 | 0.04 | Why? |
| Rectum | 1 | 2019 | 495 | 0.04 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.04 | Why? |
| Child | 3 | 2020 | 70012 | 0.04 | Why? |
| Evidence-Based Medicine | 1 | 2008 | 3228 | 0.04 | Why? |
| Nasal Cavity | 1 | 2020 | 909 | 0.03 | Why? |
| Host-Pathogen Interactions | 1 | 2014 | 11041 | 0.03 | Why? |
| Protective Factors | 1 | 2020 | 1720 | 0.03 | Why? |
| Genes, Viral | 1 | 2019 | 1428 | 0.03 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.03 | Why? |
| Sequence Alignment | 1 | 2020 | 2109 | 0.03 | Why? |
| Spatial Analysis | 1 | 2019 | 878 | 0.03 | Why? |
| Immunohistochemistry | 1 | 2021 | 2275 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.03 | Why? |
| Developing Countries | 1 | 2008 | 4283 | 0.03 | Why? |
| Cluster Analysis | 1 | 2020 | 3001 | 0.03 | Why? |
| Travel | 2 | 2020 | 7220 | 0.03 | Why? |
| Lung | 1 | 2020 | 31049 | 0.03 | Why? |
| Macaca mulatta | 1 | 2021 | 3716 | 0.03 | Why? |
| High-Throughput Screening Assays | 1 | 2020 | 1783 | 0.03 | Why? |
| Treatment Outcome | 1 | 2017 | 51732 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Severity of Illness Index | 1 | 2017 | 48226 | 0.02 | Why? |
| Aged | 6 | 2020 | 215776 | 0.02 | Why? |
| Basic Reproduction Number | 1 | 2020 | 2676 | 0.02 | Why? |
| Lymphocytes | 1 | 2021 | 3056 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.02 | Why? |
| Antimalarials | 1 | 2020 | 2505 | 0.02 | Why? |
| Iran | 1 | 2020 | 5467 | 0.02 | Why? |
| Infant | 2 | 2020 | 30274 | 0.02 | Why? |
| Epidemiological Monitoring | 1 | 2020 | 3493 | 0.02 | Why? |
| Treatment Refusal | 1 | 2008 | 211 | 0.02 | Why? |
| Child, Preschool | 2 | 2020 | 36283 | 0.02 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2020 | 3388 | 0.02 | Why? |
| Drug Discovery | 1 | 2020 | 3092 | 0.02 | Why? |
| AIDS-Related Opportunistic Infections | 1 | 2008 | 260 | 0.02 | Why? |
| Italy | 2 | 2020 | 38444 | 0.02 | Why? |
| Predictive Value of Tests | 1 | 2020 | 9537 | 0.02 | Why? |
| Intubation, Intratracheal | 1 | 2020 | 3962 | 0.02 | Why? |
| Molecular Docking Simulation | 1 | 2020 | 6902 | 0.02 | Why? |
| Infant, Newborn | 2 | 2020 | 23105 | 0.02 | Why? |
| Herpes Genitalis | 1 | 2004 | 90 | 0.02 | Why? |
| Protease Inhibitors | 1 | 2020 | 3630 | 0.02 | Why? |
| Research Design | 1 | 2020 | 5830 | 0.02 | Why? |
| Herpesvirus 2, Human | 1 | 2004 | 137 | 0.02 | Why? |
| Monocytes | 1 | 2014 | 2978 | 0.01 | Why? |
| Specimen Handling | 1 | 2020 | 6190 | 0.01 | Why? |
| Viral Proteins | 1 | 2020 | 7370 | 0.01 | Why? |
| Pneumonia | 1 | 2021 | 5652 | 0.01 | Why? |
| Gonorrhea | 1 | 2004 | 315 | 0.01 | Why? |
| Risk-Taking | 1 | 2004 | 508 | 0.01 | Why? |
| Syphilis | 1 | 2004 | 318 | 0.01 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2014 | 4545 | 0.01 | Why? |
| Cell Line | 1 | 2014 | 12040 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Cohort Studies | 2 | 2014 | 36005 | 0.01 | Why? |
| Critical Illness | 1 | 2020 | 17281 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.01 | Why? |
| Sexual Behavior | 1 | 2004 | 1322 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2008 | 7268 | 0.01 | Why? |
| Antibodies, Neutralizing | 1 | 2021 | 25288 | 0.01 | Why? |
| Virus Replication | 1 | 2014 | 14331 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.01 | Why? |
| Algorithms | 1 | 2008 | 7346 | 0.01 | Why? |
| Infectious Disease Transmission, Vertical | 1 | 2008 | 5164 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2020 | 88759 | 0.01 | Why? |
| Sex Factors | 1 | 2004 | 11014 | 0.00 | Why? |
| Pregnancy | 1 | 2008 | 23879 | 0.00 | Why? |
| Prospective Studies | 1 | 2004 | 43301 | 0.00 | Why? |